Veterinary & Animal Health Biologics

Veterinary & Animal Health Biologics (USDA CVB) — CDMO Services

Design → Licensure → Supply. A microbial-first CDMO for species-tuned biologics—engineered probiotics (LBPs), enzymes, bacterins and VLPs, and bacteriophages—for companion animals and production species. We build USDA CVB-ready CMC packages, execute pilot/conditional licensure, and deliver farm-scale formulations that actually work in the real world.

Executive overview

Animal health is not human health with different labels. Species differ in anatomy, immunity, microbiome, dosing logistics, and economics; regulators differ in dossiers, language, and serial release philosophy. Success requires a CDMO that is fluent in USDA APHIS Center for Veterinary Biologics (CVB) frameworks, and at the same time immersed in microbial manufacturing where most veterinary biologics live: LBPs, bacterins, VLPs, OMVs, enzymes, and phage.

Mika Biologics runs veterinary programmes end-to-end. We align QTPP → CQAs → CPPs around species and route, build scale-down models that mimic farm and field constraints (temperature swings, water systems, feed matrices), and manufacture DS/DP at scales that make sense—from small runs for pilot or conditional licensure through steady commercial supply with farm-scale packaging. Dossiers are shaped for USDA CVB: Outline of Production, Special Outlines, Master Seeds/Cells, serial release and potency logic, purity/safety narratives, and environmental risk where genetic modifications are in play. When you need environmental challenge studies, we orchestrate them with vetted CRO partners and fold the data back into label claims and renewal dossiers.

The outcome is pragmatic: species-specific biologics that behave on farm and in clinic, documentation that survives inspection, and a supply chain that keeps vets and producers stocked.

Our Animal Health Capabilities

  • Species-tuned modalities
    • Live Biotherapeutic Products (LBPs): single strains and defined consortia tailored for canine, feline, equine, bovine, ovine, caprine, swine, poultry, aquaculture (salmonids, shrimp), camelids, cervids, and exotics where justified.
    • Enzymes: oral and feed-integrated enzymes (e.g., toxin degraders, fibre modulators) with rumen/foregut or hindgut targeting; topical/otic enzymes where indicated.
    • Bacterins / Toxoids / VLPs / OMVs: fermentation-based vaccines with clean potency and purity stories; in ovo and spray vaccination options for poultry; immersion/bath for aquaculture.
    • Bacteriophages & phage-derived enzymes: targeted antimicrobials for enteric, respiratory, and mastitis-adjacent indications; water-line and bolus delivery concepts.
  • USDA CVB regulatory deliverables
    • CMC packages written to CVB expectations: Outline of Production (OOP), Special Outlines, Master Seed/Cell files, serial release test plans, potency reference strategies, and in-process controls that speak 9 CFR language.
    • Establishment and Product support for pilot and conditional licensure, and conversion to full licensure with comparability protocols for process/mfg site evolution.
    • Label and claims alignment with potency data; lot release and stability plans mapped to serial testing logic.
    • Environmental and biosafety narratives for engineered strains and recombinant products.
  • Formulation & presentation
    • Feed, chew, capsule, bolus, paste, drench, sachet formats; water-soluble powders and water-med packs for barns and hatcheries; intranasal sprays, topical/otic, and parenteral presentations where applicable.
    • Lyophilised and liquid options with dose-calibrated CFU/PFU/particle counts; palatability matrices (beef/chicken/fish) for pets; controlled-release or enteric protection for ruminants and hindgut targets.
    • Farm-scale packaging (pails, carboys, bag-in-box, multi-dose vials, drum concentrates) qualified for temperature and handling realities.
  • Environmental challenge & stability
    • Challenge models at partner CROs (GLP/appropriate biosafety) with species-specific endpoints; stress testing for water quality, temperature cycling, vibration/shock, UV, and feed process interactions.
    • ICH-informed stability where helpful, plus farm-specific robustness (freeze-thaw, barn ambient, repeated opening/closing) for realistic expiry and in-use claims.

Why veterinary biologics behave differently

  • Regulatory centre-of-gravity: In the US, veterinary biologics are supervised by USDA APHIS CVB, not FDA/CBER. CVB’s worldview emphasises Outline of Production, serial consistency, and master seeds, and expects simple, defendable potency tests that map to label claims in the species of use.
  • Species pharmacology & logistics: Rumen pH, gizzard mechanics, hindgut fermentation, and avian respiratory anatomy are not academic details—they decide if your biologic survives to the site of action. Routes that work in human clinics (e.g., cold-chain parenterals) can be impractical in barns or on boats.
  • Economics: A per-dose cost that is routine for a monoclonal in humans may be untenable for a flock. Processes must be designed for COGS and scale without abandoning quality.
  • Microbes matter: Most veterinary biologics are microbial products—LBPs, bacterins, phage, VLPs—so microbial process discipline (oxygen, shear, endotoxin/lipids, residual DNA, environmental containment) is the main lever.

Mika Biologics is built for this world.

Programme design: QTPP → CQAs → CPPs (species first)

Every programme begins with an explicit map that everyone can hold.

QTPP examples

  • Species/breed categories and age bands; target route (oral bolus, feed inclusion rate, drinking water ppm, intranasal spray, in ovo, immersion, subcutaneous, intramammary).
  • Dose and regimen (single vs multiple; per kg or per head); on-farm administration constraints (drench guns, medicators, sprayers).
  • Storage (ambient vs 2–8 °C vs frozen/lyo), in-use window (once opened), and label shelf-life targets.
  • Claims (e.g., reduces severity of X; aids in control of Y; supports Z function) tied to practical potency read-outs.

CQAs

  • Identity and purity appropriate to modality (genome/markers for LBPs and phage; antigen content and particle metrics for VLPs/OMVs; enzyme unit activity in relevant matrix).
  • Potency that tracks label claim (CFU-normalised payload release; PFU and EOP; antigen units per dose; enzyme units per g of feed or per mL water).
  • Safety (bioburden/sterility as applicable; endotoxin for parenterals; residual DNA/host proteins; antibiotic-resistance gene policy).
  • Stability (dose-delivering CFU/PFU/antigen units across label life; robustness to farm shocks).
  • Palatability and administration performance for companion animals.

CPPs

  • Upstream: ORP/DO for anaerobes, infection kinetics for phage, methanol/redox for Pichia antigens, vesiculation stress for OMVs, fermentation pH/osmolality for enzymes.
  • Downstream: TFF flux/ΔP, nuclease exposure, column load/residence, conductivity/pH windows, shear exposure during formulation.
  • Presentation: granulation particle size; lyo residual moisture; headspace oxygen; coating thickness for enteric boluses; spray droplet spectrum for intranasal delivery; in ovo dosing uniformity.

The control strategy that falls out of this map then writes your Outline of Production almost by itself.

Modalities and species-specific execution

Engineered Probiotics (LBPs)

Chassis: E. coli Nissle, Lactobacillus, Bifidobacterium, Bacteroides/Clostridia for hindgut/colon, and species-native isolates where evidence supports them. For ruminants, we balance rumen survival with targeting the abomasum or hindgut as required.

Safety architecture: chromosomal integration (plasmid-free final strains where possible), absence of mobile AR genes, auxotrophies, and kill-switches that do not trigger under manufacturing/storage conditions but do reduce environmental persistence outside the intended niche.

Formulation:

  • Companion animals: palatable chews, capsules, or sprinkle-on sachets; moisture and oxygen budgets for pantry storage; CFU per chew controlled tightly.
  • Production species: feed premix granules with flow and dust characterisation, top-dress sachets, drench concentrates, and drinking-water powders compatible with medicators.
  • Aquaculture: immersion baths and water-line dosing, with salinity and temperature stability built in.

Potency: CFU release aligns to route; for functional LBPs (payload enzymes or immunomodulators), we specify payload activity per dose in the relevant matrix (e.g., rumen-like pH and salt).

Enzymes

Targets: rumen modifiers, toxin degraders (e.g., mycotoxin-adjacent programmes), feed digestibility enhancers, otic/topical enzymes for companion animals, water-system biofilm solutions.

Manufacturing: microbial expression (E. coli or Pichia) with endotoxin control (for parenterals) or feed-safe impurity logic; granulation/coating for feed and bolus; lyo for sachets and capsules.

Assays: enzyme units/mg in feed mash or water matrices; in-use stability across daily temperature swings; compatibility with common feed additives and ion profiles.

Bacterins, VLPs, and OMVs

Antigen sourcing: killed cultures (bacterins), engineered VLP/OMV scaffolds expressing species-relevant epitopes, with adjuvant compatibility where label permits.

Process: TFF capture; SEC or ion-exchange polishing; particle analyses (NTA/DLS/EM) aligned to potency; endotoxin/purity stories suitable for route (injectable vs mucosal).

Species routes:

  • Poultry: spray and drinking-water administration; in ovo dosing compatibility.
  • Aquaculture: immersion and bath with salinity-temperature windows.
  • Companion animals & equine: injectable and intranasal options.

Potency & stability: antigen units per dose; particle integrity and size windows; adjuvant stability; multi-dose vial stability under field handling.

Bacteriophages & phage-derived enzymes

Use-cases: enteric Salmonella/E. coli, respiratory-adjacent settings via aerosolisation, mastitis-adjacent hygiene concepts, aquaculture waterline applications.

Manufacturing: lytic phage seeds and host banks; infection/lysis kinetics; TFF + AEX for purity; aseptic closed processing (no 0.22 µm filtration); DP buffers that protect tails and capsids.

Presentation: water-line concentrates, bolus/capsule for targeted delivery, aerosol compatible formulations for hatcheries or barns, and lyo where logistics benefit.

Potency: PFU per dose; EOP on target strains from the species/geography of interest; stability at barn ambient and chilled transport.

USDA CVB dossiers: what we assemble and how

  • Outline of Production (OOP): plain-language process narrative for each step—upstream, downstream, formulation, filling—and the sampling and tests at each node; includes hold times, in-process controls, and serial release plan.
  • Special Outlines: shared procedures (e.g., sterility, potency assay descriptions) reused across products for consistency.
  • Master Seed/Cell files**: identity, stability, absence of adventitious agents, genetic integrity (for engineered strains), and propagation histories.
  • Serial release: potency tests (CFU/PFU/antigen units), safety/purity as appropriate, and acceptance criteria tied to label claims; for multi-antigen or cocktail products, a matrix that will survive repeat inspections.
  • Labels and claims: text that maps exactly to potency methods and challenge results; Precautions and Directions in CVB-consistent language.
  • Pilot/conditional licensure: staged data packages with reasonable expectation of efficacy where permitted; conversion to full licensure with additional field and serial data.
  • Environmental & biosafety: risk assessments for recombinant organisms and GMOs, containment SOPs, and inactivation methods for spills and waste.

We draw on our Analytical & QC team to ensure methods are phase-appropriate (repeatable, inspector-friendly) and that control strategies read cleanly.

Analytical & QC for veterinary biologics

  • Identity: WGS or strain-level PCR for LBPs; peptide mapping/LC-MS for enzymes; genome identity and morphology for phage; marker panels and EM/NTA for VLPs/OMVs.
  • Potency: CFU/dose with functional payload assays in relevant matrices; enzyme units under feed/water conditions; PFU and EOP on species-matched panels; antigen units and particle function for VLPs/OMVs.
  • Purity & safety: HCP/HCD, residual DNA, endotoxin (route-appropriate), sterility/bioburden where applicable, AR gene surveillance for LBPs.
  • Stability: ICH-style and farm-reality (freeze-thaw, thermal cycling, agitation, light, repeated opening); for waterline products, diluted-over-time potency profiles; for feed premixes, pelleting/heat simulations if needed.
  • Method transfer SLAs and reference standards that keep serials consistent year-to-year.

Formulation & presentation that farmers and vets actually use

  • Companion animals: soft chews (beef/chicken/fish flavours), sprinkle-on sachets, palatable pastes and gels, pre-measured capsules; syringeable liquids for clinics with clear in-use windows.
  • Cattle/sheep/goats: boluses with controlled-release or enteric protection, drenches, feed premix and top-dress formats with flow/dust testing; multi-dose vials for parenterals with stopper integrity that survives field use.
  • Swine: water-line powders compatible with medicators; nursery and finisher dose design; barn-temperature stability plans.
  • Poultry: hatchery-friendly concentrates, spray droplet spectra validated for coverage, in ovo dose calibration; multi-flock vial sizes and pouches.
  • Aquaculture: immersion/bath protocols at target salinities and temperatures; water-stable microencapsulated beads for feed if appropriate.
  • Equine: oral pastes and injectables with trailer-and-show temperature excursions covered.
  • Exotics/zoo: bespoke formats with keepers’ administration constraints in mind.

Packaging is sized to the job: 10-dose vials for clinics, 1000-dose waterline pouches for barns, 20–200 L carboys for hatcheries, and bag-in-box formats for hygiene and dosing simplicity. Oxygen and moisture budgets are written into labels and tested with headspace and MVTR analytics.

Environmental challenge & partner CRO orchestration

Mika coordinates GLP-appropriate challenge studies with partners who know the species and the pathogens. We define endpoints that match claims (e.g., reduction in pathogen load, improvement in clinical scores, performance metrics), align statistical power to CVB expectations, and ensure husbandry and biosecurity are documented. For waterline and spray products we run distribution and persistence studies so label directions reflect reality. After study close, we compile datasets into the efficacy and safety narratives your licensing path requires.

Process characterisation, PPQ & CPV (veterinary edition)

We qualify scale-down models that capture oxygen transfer, mixing, ORP (for strict anaerobes), infection kinetics (phage), vesicle shear and residence times (OMVs), and pelleting/heat exposures where feed is involved. Design spaces are written for simplicity and transferability; three-batch PPQ closes with acceptance criteria grounded in real capability. CPV dashboards watch the few historian tags that predict CQAs—TFF flux/ΔP, column conductivity/UV profiles, lyo Pirani–capacitance convergence, headspace oxygen—and flag drift before release metrics move.

Digital QMS and serial documentation

Our eBatch/LIMS backbone enforces ALCOA+ from assay to label: analyst IDs, instrument IDs, audit trails, versioned SOPs, and raw data retention. DHRs assemble themselves as batches run; serial release tables are pre-populated; APR/PQR exports are one-click. When inspectors arrive, the story is already in order.

Costings, supply, and logistics thinking

Veterinary programmes live or die on logistics and cost:

  • COGS: we design unit operations (e.g., PCC capture, membrane adsorbers) for resin efficiency and water/energy use; feed premixes and waterline products avoid unnecessary cold-chain.
  • Supply assurance: second-source materials, resin life tracking, filter interchangeability, and flexible filling lines accommodate seasonality (calving, chick placement, holiday pet surges).
  • Distribution: ambient or 2–8 °C shipping validated; shock/vibration profiles for farm roads; label and IFU text lines up with what drivers and techs can actually do.

Illustrative species & format matrix (examples)

  • Companion (canine/feline): LBP chews (≥ 10⁹ CFU/chew), enzyme capsules, intranasal VLP; 24-month shelf-life at ambient for chews (moisture ≤ X%, headspace O₂ ≤ Y%).
  • Equine: oral paste LBP with syringe plunger force validated from 5 °C to 30 °C; VLP/OMV parenteral with 10-dose vial stability after first puncture.
  • Bovine: feed premix enzymes; phage water-line concentrate; multi-dose vial bacterin for subcutaneous dosing with rubber closure integrity through 20 punctures.
  • Swine: nursery water-line LBP; aerosol-compatible phage; premix enzyme compatible with common medicators and feed acids.
  • Poultry: hatchery spray VLP; in ovo compatible antigen; OMV drinking water product with biofilm-resistant diluent logic.
  • Aquaculture: immersion VLP with salinity-stable buffers; LBP in coated feed microbeads with time-to-sink profiles.
  • Small ruminants & camelids: bolus LBP; bacterin multi-dose vials with flock-sized presentations.
  • Cervids/exotics: bespoke dosing devices; packaging sized to herd/collection.

Sample COA excerpts (veterinary)

LBP Chew — Canine (beef flavour)

  • Identity: strain PCR panel matches MCB
  • CFU/chew: ≥ 1.0 × 10⁹ (spec ≥ 1.0 × 10⁹)
  • Payload activity: ≥ spec (enzyme Units/chew)
  • Moisture: 6.5% (spec ≤ 8.0%)
  • Headspace O₂: 0.8% (spec ≤ 1.5%)
  • Palatability panel: pass (n= X)
  • Microbiology (pathogens): negative
  • Stability: Month 12 ambient within acceptance

Phage Water-Line Concentrate — Swine

  • Identity: WGS confirmed; lytic only; no toxin/ARG loci
  • Titer (PFU/mL): 2.0 × 10¹¹ (spec ≥ 1.0 × 10¹¹)
  • EOP coverage: meets panel matrix
  • Endotoxin: in band for route
  • Appearance/pH: clear, in range
  • Stability: Month 6 at barn ambient PFU loss ≤ 0.2 log

VLP Spray — Poultry

  • Particle count (NTA): ≥ X particles/mL
  • Size mode: 90–120 nm
  • Antigen display ELISA: ≥ spec
  • Spray droplet Dv50: in spec for hatchery device
  • Sterility: pass
  • Stability: 2–8 °C Month 12 in band

Enzyme Feed Premix — Bovine

  • Units/g (feed matrix): ≥ spec across pH and temp band
  • Granule size: d50 in spec; dust index pass
  • Moisture: ≤ spec
  • Compatibility: no loss with common feed acids at use-rates
  • Stability: 6 months ambient; heat excursion pass

Onboarding in 30 days

  • Day 10: QTPP→CQA→CPP sheet; species routes and farm logistics captured; draft Outline of Production skeleton; risk register.
  • Day 20: Scale-down qualification plan; preliminary formulation menus (chew/capsule/feed/waterline/spray); stability and challenge study outlines with partner CRO slots.
  • Day 30: Draft control strategy; first engineering lots scheduled; CVB dossier index (OOP, Special Outlines, seeds/cells, serial plan, labels); packaging matrix by channel (clinic, farm, hatchery).

Why Mika for veterinary biologics

  • Species fluency across pets, herd animals, poultry, aquaculture, camelids, cervids, and exotics.
  • Microbial mastery for LBPs, bacterins, VLPs/OMVs, enzymes, and phage—where animal health lives.
  • CVB-native dossiers that use the regulator’s language (OOP, Special Outlines, serial logic) and anticipate questions.
  • Formulations that work in barns, hatcheries, boats, and clinics—not just in conference rooms.
  • Challenge orchestration with partners who understand field realities.
  • Scale and cost discipline that honour per-dose economics without compromising quality.

Inter-page guidance

  • Pair with Engineered Probiotics (LBP) — GMP Manufacturing for chassis, kill-switches, and anaerobic suites.
  • Use Analytical & QC for Microbial Biologics for potency panels, particle analytics, and rFC/LAL strategy.
  • See Formulation & Aseptic Fill-Finish (Grade A Isolators) for lyo, CCI, and multi-presentation fills.
  • Cross-reference Bacteriocins & Lantibiotics, Phage Therapeutics & Enzymes, Exosomes & OMVs, and Advanced Yeast Glycoengineering where your pipeline overlaps.
  • For lifecycle control, Process Characterization, PPQ & CPV makes PPQ and CPV straightforward.

Animal CDMO FAQ

1) Are veterinary biologics regulated like human biologics?
In the US, most veterinary biologics are regulated by USDA APHIS Center for Veterinary Biologics (CVB), not FDA. CVB dossiers revolve around an Outline of Production (OOP), Special Outlines, Master Seed/Cell governance, and serial (lot-by-lot) potency and safety testing aligned to species, route, and label claims. The OOP is the binding control strategy: any meaningful process, test, or specification change must be pre-cleared via supplement.

2) What is conditional licensure and how do we convert to full licensure?
Conditional licensure can be granted on a reasonable expectation of efficacy with complete safety, purity, and manufacturing controls. We design an evidence plan that includes pivotal challenge or field data, then execute the additional studies, serial consistency, and method robustness required to convert to full licensure on an agreed timeline.

3) Which species and administration routes do you support?
Companion (canine/feline), equine, bovine, ovine/caprine, swine, poultry (spray, in ovo, drinking water), aquaculture (immersion/bath, feed), camelids, cervids, and select exotics. Routes include oral (chew, bolus, paste, drench, waterline), parenteral, intranasal spray, in ovo, immersion, and topical/otic presentations, with device and user constraints validated.

4) Which modalities do you manufacture?
Live Biotherapeutic Products (LBPs), bacteriophages and phage-derived enzymes, bacterins/toxoids, VLPs/OMVs, and enzymes (oral, feed-integrated, topical). Each has a tailored USP/DSP, analytics, and release logic consistent with CVB expectations.

5) How do you design feed or waterline products that survive farm realities?
We test in realistic matrices: feed acids, pelleting or mash temperatures, water hardness/chlorination/iron, medicator compatibility, and barn temperature cycles. Data drive excipient choices, microencapsulation/coatings, MVTR targets, oxygen budgets, and IFU directions (e.g., dose vs ppm vs flock size), then become enforceable specs and label statements.

6) Can you manage palatability and dose uniformity for companion-animal chews/pastes?
Yes. We run palatability panels, flavour screens (beef/chicken/fish), and texture/rheology studies, balancing taste with CFU/PFU/antigen units and excipient stability. We control moisture and headspace O₂, set water activity limits, and qualify per-unit content uniformity so each chew/paste delivers the label dose.

7) How are environmental and biosafety risks addressed for engineered strains?
By kill-switches, auxotrophies, chromosomal integration (plasmid-free where possible), removal of mobile antibiotic-resistance elements, and documented inactivation procedures (heat/chemical) for spills and waste. We draft the environmental-risk narrative and site SOPs that support facility biosafety and dossier needs.

8) Do you run challenge studies yourselves?
We orchestrate GLP-appropriate challenges with specialist CROs. We define endpoints that match label claims, randomisation/blinding, power and effect sizes, husbandry and biosecurity controls, and analytical readouts. Data return into efficacy and safety narratives and inform label text and serial potency specifications.

9) Can you supply multi-dose farm packaging?
Yes. Pails, carboys, bag-in-box, multi-dose vials, drum concentrates—with validated seals, CCI/closure integrity, headspace control, shock/vibration and temperature cycling, and dispensing compatibility (medicators, drench guns, hatchery sprayers).

10) Do you support launches outside the US?
Yes. We prepare cross-walks and data packages for other jurisdictions (e.g., immunological veterinary medicinal product frameworks), aligning terminology, potency logic, environmental narratives, and labelling while preserving your data spine.

11) What goes into an Outline of Production (OOP)?
A stepwise, auditable description of upstream, downstream, formulation, filling, in-process tests, acceptance criteria, hold times, yields, sampling plans, and serial release tests. It includes materials and equipment critical to quality. The OOP must be internally consistent with Special Outlines, seeds/cells files, and labels.

12) How are Special Outlines managed?
Special Outlines cover shared procedures (e.g., sterility tests, specific potency methods, environmental monitoring). We version-control them, ensure cross-product harmonisation, and pre-plan supplements so updates land once across the portfolio without breaking product dossiers.

13) What is required for Master Seed/Cell files?
Identity (genomic markers/WGS where appropriate), purity (freedom from adventitious agents), stability (genetic/phenotypic), safety, and propagation histories. For phage: strictly lytic biology, absence of toxins/ARGs; for engineered strains: integration maps and stability; for antigen seeds: clonal and contamination checks.

14) How are serial release tests designed?
They must be simple, repeatable, and claim-linked. Examples: CFU per dose with functional payload assay; PFU with EOP on a defined strain panel; antigen units and particle integrity for VLP/OMV; enzyme Units in feed/water matrices. Safety (sterility/bioburden as applicable) and purity (residual DNA/protein, endotoxin for injectables) complete the panel.

15) How are potency references controlled across serials?
We create and maintain reference standards or control serials with defined acceptance windows. We run periodic bridging when references change, document drift detection logic, and lock calibration factors so potency claims are stable across years.

16) What validation do potency assays require?
Phase-appropriate specificity, precision, accuracy/linearity, reportable range, and robustness for the matrix and species. For waterline/spray/in ovo routes, we include device/delivery variability and in-use factors (temperature, pH, dwell time) within robustness.

17) How are endotoxin and residual DNA handled for veterinary injectables?
We design processes to reduce LPS (host/media choice, AEX/TFF) and quantify via LAL or recombinant Factor C where appropriate, with method suitability (inhibition/enhancement) demonstrated. Residual DNA (host-specific qPCR/ddPCR) is set to route-appropriate limits and trended.

18) What does comparability/change control look like under CVB?
We pre-define assay panels and acceptance bands that carry the sameness argument (potency, purity, particle metrics/CFU/PFU/antigen units; key physicochemical attributes). We classify changes (minor/major), prepare supplements, and, when needed, run side-by-side batches or bridging serials to defend equivalence.

19) How do you structure environmental monitoring (EM) for microbial manufacturing?
Programme-specific active/passive air, surface swabs, and personnel EM, with action/alert levels tied to operations (e.g., open manipulations, aseptic fills). For LBPs/phage/OMV, we add organism-specific markers (e.g., phage presence screens). Trends feed CAPA and CPV dashboards.

20) What sterility/bioburden policies do you apply?
Route-dependent. For non-filterable products (phage/OMV/EV) we validate closed aseptic processing and release on pharmacopoeial sterility tests; for oral/feed products we set bioburden and pathogen panels appropriate to species and use. Media fills support aseptic steps; hold times are validated.

21) How are stability programmes designed for barns, hatcheries, and boats?
We run real-time and excursion studies aligned to label storage plus farm-reality stresses: freeze-thaw cycles, daily thermal cycling, agitation, light, repeated opening, chlorinated water exposure, medicator dwell. Acceptance criteria are claim-linked: CFU/PFU/antigen units/function within bands at expiry and in-use.

22) How do you qualify cold-chain and ambient shipping?
IST-temperature profiles with loggers for lane simulations; shaker and drop tests for rough handling; seasonal profiles (summer/winter). Acceptance is functional (potency/particle metrics/CFU) and physical (container integrity/headspace oxygen).

23) How are waterline doses calibrated and controlled?
We convert label doses to ppm/mg/L with medicator calibration and back-calculation from barn flow rates. We qualify solubility, dosing uniformity over time, and recovery at representative plumbing dead-legs. Device tolerances enter the robustness claim.

24) What makes spray and in ovo programmes succeed?
For spray: droplet spectrum (Dv10/Dv50/Dv90) matched to hatchery devices and bird age, surfactant policies that protect particles/cells, and distribution mapping across trays. For in ovo: needle and dose accuracy, egg position, embryo safety, and sterility at the point of dose.

25) How do you protect enzymes through pelleting and feed processing?
By choosing granulation size, coatings (lipid/polymer), and protectants that survive steam conditioning and pelleting temperatures; we run post-pellet activity tests across feed recipes and acids. If pelleting kills activity, we pivot to post-pellet liquids or top-dress sachets.

26) How do you target the rumen vs hindgut in ruminants?
Bolus coatings and enteric systems tuned to pH and transit time; for rumen retention we use density/geometry and matrices that resist early washout. We verify site-of-release with in vitro rumen models and in vivo marker studies.

27) How do you write labels and IFUs vets and farm staff actually follow?
By aligning units and devices to on-farm practice: dosing calculators (per head, per 1,000 birds, per m³ water), device settings (medicator %, sprayer nozzles), pictograms, and language packs. We prove readability with usability/competency checks and tie IFU constraints to stability and potency data.

28) What analytics distinguish microbial modalities?
LBP: CFU with functional payload assays; strain ID by PCR/WGS; kill-switch challenge. Phage: PFU, EOP on a clinical panel, genome identity, endotoxin. VLP/OMV: NTA/DLS/EM convergence, antigen display ELISA, endotoxin/purity. Enzymes: Units/mg in target matrix, SEC-MALS (aggregates), residuals. All are trended and bridged to serial release logic.

29) How do you exclude adventitious agents in bacterial or phage seeds?
Seed qualification includes freedom from contaminating phage (for bacterial producers), mycoplasma (if relevant), pathogen panels appropriate to host, and genomic checks. For phage, strictly lytic behaviour and genome scans for toxins/ARGs are documented.

30) What waste management and inactivation controls are in place?
Validated thermal and chemical inactivation for liquid and solid waste; segregation of pre- and post-process zones; HEPA filtration for exhaust where aerosol risks exist; documented spill responses and verification assays for post-clean residuals.

31) How do you enforce data integrity and batch traceability?
An eBatch/LIMS backbone with ALCOA+: analyst/instrument IDs, time-stamped audit trails, versioned SOPs, raw files attached (chromatograms, micrographs, NTA reports), and automatic trend plots. DHRs assemble as the batch runs; APR/PQR exports are generated directly from the system.

32) How are PPQ and CPV tailored to animal health programmes?
Three-batch PPQ at scale with proven scale-down fidelity; acceptance criteria reflect real capability (Cp/Cpk), not aspirational specs. CPV dashboards track the few historian tags that predict CQAs—TFF flux/ΔP, column conductivity/UV profiles, lyo Pirani–capacitance convergence, headspace oxygen—so drift is corrected before release metrics move.

33) Can you integrate companion diagnostics or field test kits into the programme?
Yes, when the claim and biology warrant it. For example, phage or LBP programmes may benefit from on-farm titer/CFU checks or environmental monitoring kits. We can manufacture IVD components under ISO 13485 and align kit performance to veterinary use.

34) What is your approach to microbiological EM action responses?
We define alert/action levels by area classification and operation, trend excursions (organism ID, CFU counts), trigger targeted clean/requalify steps, re-sample on tightened intervals, and assess product impact via hold-time and open-exposure logs. CAPA closes with demonstrated trend recovery.

35) How do you manage raw material variability (resins, membranes, excipients)?
Approved supplier lists with dual sourcing, incoming tests (e.g., ligand density, endotoxin, microbial limits), small-scale resin life and fouling index tracking, excipient identity/assay/bioburden, and bridging if materials change. All are linked to OOP supplements where needed.

36) Can we run cocktails (multi-phage, multi-strain, multi-antigen) without constant supplements?
Yes—if we pre-define a cocktail governance plan: composition windows, comparability assays, and change-control triggers that let you swap components within an approved matrix. We align this with CVB so routine drift management doesn’t become perpetual paperwork.

37) How do you justify in-use periods for multi-dose vials on farm?
Through puncture simulation, closure reseal testing, bioburden/stability after repeated withdrawals at barn temperatures, and label-specific IFU constraints (e.g., “use within X hours” or “refrigerate between uses”). CCI and preservative policies are backed by data.

38) What if 0.22 µm sterilising filtration is incompatible (phage/OMV/EV)?
We design closed aseptic processing with validated bioburden control, media fills mirroring worst-case holds, and sterility at release. The dossier explains filtration infeasibility and documents barriers that achieve an equivalent assurance of sterility.

39) How do you keep potency assays inspector-friendly yet predictive?
We avoid fragile, multi-step cell systems when a robust surrogate will do, but we ensure mechanism relevance (e.g., antigen display + functional activation; CFU plus payload release). Orthogonal readouts (e.g., NTA with EM, PFU with EOP) build confidence without algorithmic gymnastics.

40) Can you stage capacity for seasonal demand (calving, chick placement, holiday pet surges)?
Yes. We plan campaigning, safety stock, flexible fill lines (vials/PFS/pouches/pails), and raw material reservations. CPV helps forecast trends so you scale deliberately, not reactively.

41) How do you ensure waterline products don’t foul lines or precipitate?
By solubility mapping vs temperature/ionic load, anti-scalant or sequestrant policies, surfactant screens that don’t harm microbes/particles, and resuspension checks. IFUs include flush steps and medicator settings validated in farm plumbing mockups.

42) Do you support combination products (e.g., LBP + enzyme, phage + bacterin)?
Yes. We write compatibility matrices, staggered dosing IFUs where needed, and stability/potency cross-checks that prevent antagonism. The label and OOP spell out co-administration constraints.

43) How do you manage label claims to avoid overreach?
We bind claims to measurable endpoints proven in target species and matrices, avoid human-health terms, and ensure wording matches potency tests. We pre-brief regulators on intent to align expectations before pivotal work.

44) Can you take over an existing USDA-licensed product and scale/improve it?
Yes. We run a gap analysis (OOP, Special Outlines, seeds/cells, release methods), recreate the control strategy where needed, validate changes via comparability and supplements, and then execute PPQ/CPV so the product is stable at new scale.

45) What are typical onboarding milestones for a new animal programme?
Day 10: QTPP→CQA→CPP sheet, draft OOP skeleton, risk register. Day 20: scale-down and stability/challenge outlines, packaging concepts. Day 30: control strategy draft, first engineering lots plan, CVB dossier index, CRO slots pencilled for challenge.